ROCKVILLE, Md., Aug. 30 Stem cell company,Neuralstem, Inc. (Amex: CUR), today announced it has entered into acollaborative agreement with the ALS Clinic at University of Michigan HealthSystem, directed by Dr. Eva Feldman, M.D., Ph.D., the De Jong Professor ofNeurology at the U-M Medical School. The goal of the collaboration is toprovide further proof-of-principle data to move Neuralstem's spinal cord stemcells into patients with Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig'sdisease. ALS is a motor neuron disease, which strikes people between the agesof 40 and 70. As many as 30,000 Americans have the disease at any given time.
"We are honored and excited to be working with Dr. Feldman and theUniversity of Michigan ALS Clinic," said Neuralstem CEO, Richard Garr. "It isnot only a world class research organization, but also clearly dedicated to,and deeply involved in, the care and treatment of the ALS patients themselves.Dr. Feldman and her team will be a tremendous partner in helping us to achieveour goal, which is to be able to treat ALS patients with our Neuralstemcells."
"We are excited about working with Neuralstem's technology and exploringthe ways in which it might lead to treatment for ALS patients," said Dr.Feldman, who is also the Director at the U-M Program for Neurology Researchand Discovery, "At the Michigan ALS clinic, we are working as hard and as fastas we can to try to find treatments for this terrible disease."
Neuralstem's patent-protected technology enables, for the first time, theability to produce neural stem cells of the human brain and spinal cord incommercial quantities, and the ability to control the differentiation of thesecells into mature, physiologically relevant human neurons and glia. TheCompany expects that its first Investigational New Drug (IND) application willbe for the treatment of Ischemic Paraplegia, a form of paraplegia thatsometimes results from the surgery to repair aortic aneurysms and for whichthere is no effective treatment. The Company hopes to submit its initial INDapplication to the FDA and begin its first human trial during calendar year2007.
Major Central Nervous System diseases targeted by the Company withresearch programs currently underway include: Ischemic Paraplegia, TraumaticSpinal Cord Injury, ALS, and Parkinson's disease. The company's cells recentlyextended the life of rats with ALS (Lou Gehrig's disease) in a paper publishedin the journal TRANSPLANTATION, and were deemed viable for continued work inneurodegenerative spinal conditions. Neuralstem cells also recently reversedparalysis in rats with Ischemic Spastic Paraplegia, a form of paralysis thatcan result from the surgery to repair aortic aneurysms, as reported inNEUROSCIENCE (http://www.neuroscience-ibro.com/ ). The company has alsodeveloped immortalized human neural stem cells for in-vitro use in drugdevelopment for the academic and pharmaceutical markets. For furtherinformation, please visit http://www.neuralstem.com .
Cautionary Statement Regarding Forward Looking Information
This presentation may contain forward-looking information aboutNeuralstem, Inc. which are intended to be covered by the safe harbor forforward-looking statements provided by the Private Securities LitigationReform Act of 1995. Forward- looking statements are statements that are nothistorical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should,""project," "plan," "seek," "intend," or "anticipate" or the negative thereofor comparable terminology, and include discussions of strategy, and statementsabout industry trends and Neuralstem's future performance, operations andproducts. This and other "Risk Factors" contained in Neuralstem's publicfilings with the SEC should be read in connection with this release. Forfurther